PBRM1 and renal cell carcinoma: We found that in pan-cancer, patients with PBRM1 mutation showed better outcomes in OS, while renal cell carcinoma patients with gene alternatives in PBRM1 illustrated no significant correlation with better or poor prognosis in OS compared with patients without PBRM1 alterations (Figures 3(c) and 3(d)).